Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Alpha-1-antitrypsin and its variant-dependent role in COVID-19 pathogenesis
Christian S. Stevens, Kasopefoluwa Y. Oguntuyo, Shreyas Kowdle, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection
Lukas Wettstein, Tatjana Weil, Carina Conzelmann, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 117
Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2–Priming Protease TMPRSS2
Nurit P. Azouz, Andrea M. Klingler, Victoria Callahan, et al.
Pathogens and Immunity (2021) Vol. 6, Iss. 1, pp. 55-74
Open Access | Times Cited: 99
Priming of SARS-CoV-2 S protein by several membrane-bound serine proteinases could explain enhanced viral infectivity and systemic COVID-19 infection
Pablo Fuentes‐Prior
Journal of Biological Chemistry (2020) Vol. 296, pp. 100135-100135
Open Access | Times Cited: 82
Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera
Kasopefoluwa Y. Oguntuyo, Christian S. Stevens, Chuan-Tien Hung, et al.
mBio (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 79
SARS-CoV-2 Antiviral Therapy
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Clinical Microbiology Reviews (2021) Vol. 34, Iss. 4
Open Access | Times Cited: 57
Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19
Xiyuan Bai, Joseph A. Hippensteel, Alida Leavitt, et al.
Medical Hypotheses (2020) Vol. 146, pp. 110394-110394
Open Access | Times Cited: 54
Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen
Jordi Rodon, Jordana Muñoz‐Basagoiti, Daniel Perez‐Zsolt, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 52
Post-Translational Modifications of Circulating Alpha-1-Antitrypsin Protein
Urszula Lechowicz, Stefan Rudziński, Aleksandra Jezela‐Stanek, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 23, pp. 9187-9187
Open Access | Times Cited: 44
COVID-19 infection in severe Alpha 1-antitrypsin deficiency: Looking for a rationale
Ilaria Ferrarotti, Stefania Ottaviani, Alice Maria Balderacchi, et al.
Respiratory Medicine (2021) Vol. 183, pp. 106440-106440
Open Access | Times Cited: 31
Severe COVID-19 Illness and α1-Antitrypsin Deficiency: COVID-AATD Study
Juan Luis Rodríguez Hermosa, Gianna Vargas Centanaro, María Estela González Castro, et al.
Biomedicines (2023) Vol. 11, Iss. 2, pp. 516-516
Open Access | Times Cited: 12
Proteases and variants: context matters for SARS-CoV-2 entry assays
Christian S. Stevens, Kasopefoluwa Y. Oguntuyo, Benhur Lee
Current Opinion in Virology (2021) Vol. 50, pp. 49-58
Open Access | Times Cited: 26
Targeting host cell proteases as a potential treatment strategy to limit the spread of SARS‐CoV‐2 in the respiratory tract
Ismail Amr El‐Shimy, Mahmoud Mohamed, Syed Shahzad Hasan, et al.
Pharmacology Research & Perspectives (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 24
Host genomics of COVID-19: Evidence point towards Alpha 1 antitrypsin deficiency as a putative risk factor for higher mortality rate
Atanu Kumar Dutta, Kalyan Goswami
Medical Hypotheses (2021) Vol. 147, pp. 110485-110485
Open Access | Times Cited: 16
Alpha-1 antitrypsin deficiency and recombinant protein sources with focus on plant sources: Updates, challenges and perspectives
Matthew J. McNulty, David Z. Silberstein, Brooks Kuhn, et al.
Free Radical Biology and Medicine (2020) Vol. 163, pp. 10-30
Open Access | Times Cited: 10
Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect after a Drug Repurposing Screen
Jordi Rodon, Jordana Muñoz‐Basagoiti, Daniel Perez‐Zsolt, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 10
Allicin inhibits SARS-CoV-2 replication and abrogates the antiviral host response in the Calu-3 proteome
Kirstin Mösbauer, Verena Nadin Fritsch, Lorenz Adrian, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Closed Access | Times Cited: 9
An Updated Review on Complicated Mechanisms of COVID-19 Pathogenesis and Therapy: Direct Viral Damage, Renin-angiotensin System Dysregulation, Immune System Derangements, and Endothelial Dysfunction
Shahab Falahi, Maryam Maleki, Azra Kenarkoohi
Infectious Disorders - Drug Targets (2022) Vol. 22, Iss. 7
Closed Access | Times Cited: 5
Low Prevalence of Mild Alpha-1-Antitrypsin Deficiency in Hospitalized COVID-19-Patients
D. R. Nygren, Ulrica Mölstad, Hans Thulesius, et al.
International Journal of General Medicine (2022) Vol. Volume 15, pp. 5843-5848
Open Access | Times Cited: 5
Correlation between α1-Antitrypsin Deficiency and SARS-CoV-2 Infection: Epidemiological Data and Pathogenetic Hypotheses
Andrea Vianello, Gabriella Guarnieri, Fausto Braccioni, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 19, pp. 4493-4493
Open Access | Times Cited: 7
Augmentation Therapy with Alpha-1 Antitrypsin: Present and Future of Production, Formulation, and Delivery
Annalisa Bianchera, Esra’a Alomari, Stefano Bruno
Current Medicinal Chemistry (2021) Vol. 29, Iss. 3, pp. 385-410
Closed Access | Times Cited: 6
The role of plasma serine leukocyte proteinase inhibitor in the body's defense against COVID-19
A. L. Kravtsov, С. А. Бугоркова
Journal of microbiology epidemiology immunobiology (2021) Vol. 98, Iss. 5, pp. 567-578
Open Access | Times Cited: 4
Assessment of neutrophil degranulation intensity and changes in neutrophil phenotype by FCᵧRIIIB expression level in blood of patients with COVID-19 and convalescents
A. L. Kravtsov, С. А. Бугоркова, S. N. Klyueva, et al.
Journal of microbiology epidemiology immunobiology (2022) Vol. 99, Iss. 2, pp. 172-184
Open Access | Times Cited: 2
Proteolysis and deficiency of α1-proteinase inhibitor in SARS-CoV-2 infection
О. Е. Акбашева, Л. В. Спирина, D. A. Dyakov, et al.
Biomeditsinskaya Khimiya (2022) Vol. 68, Iss. 3, pp. 157-176
Closed Access | Times Cited: 2
Auswirkungen der COVID-19-Pandemie auf das Informationsmanagement und die Therapieadhärenz von substituierten Patienten mit Alpha-1-Antitrypsin-Mangel (AATM)
Thomas Köhnlein, Marion Wilkens, Katharina Eydt
Pneumologie (2022) Vol. 76, Iss. 07, pp. 494-498
Closed Access | Times Cited: 1
Novel Cellular Stress Models with Implications in Understanding and Treating ENT Pathologies
Naresh K. Panda, Maryada Sharma, Anurag Ramavat, et al.
(2022), pp. 139-180
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top